Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

• Published in: The New England journal of medicine Vol. 382; no. 3; pp. 244 - 255
• Main Authors: Tsimikas, Sotirios, Karwatowska-Prokopczuk, Ewa, Gouni-Berthold, Ioanna, Tardif, Jean-Claude, Baum, Seth J, Steinhagen-Thiessen, Elizabeth, Shapiro, Michael D, Stroes, Erik S, Moriarty, Patrick M, Nordestgaard, Børge G, Xia, Shuting, Guerriero, Jonathan, Viney, Nicholas J, O’Dea, Louis, Witztum, Joseph L
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 16.01.2020
• Subjects: Adult; Aged; Antisense oligonucleotides; Aortic stenosis; Apolipoproteins; Blood platelets; Blood pressure; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - blood; Cardiovascular Diseases - drug therapy; Cholesterol - blood; Dose-Response Relationship, Drug; Double-Blind Method; Drug dosages; Female; Health risk assessment; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypolipidemic Agents - administration & dosage; Hypolipidemic Agents - adverse effects; Hypolipidemic Agents - therapeutic use; Influenza; Laboratories; Least-Squares Analysis; Lipoprotein(a) - blood; Low density lipoprotein; Male; Middle Aged; Oligonucleotides - administration & dosage; Oligonucleotides - adverse effects; Patients; Risk Factors; Stenosis; Urine
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1905239

Elevated levels of lipoprotein(a) in the plasma are a risk factor for cardiovascular disease, and lowering levels can be achieved with antisense oligonucleotide targeting LPA messenger RNA, which encodes lipoprotein(a). This trial tested whether the same effect can be achieved in persons with established cardiovascular disease.